The research will apply Millennium's advanced proteomics technologies and represents an expansion of Millennium's Diagnomic product development and personalized medicine initiatives into the area of rheumatoid arthritis. For Roche, this alliance provides an opportunity to further strengthen its proteomics research program to develop novel diagnostics. Through the terms of this three-year alliance, Roche obtains certain research and development rights to select diagnostic markers and related intellectual property developed by Millennium in this disease area.
Millennium receives a licensing fee, funding for research, milestone payments and royalties.
Diagnostic products resulting from the alliance will be brought to market by Roche. We are delighted to enter into this new alliance with Millennium. Through this alliance, we will have the ability to work with Millennium in applying their advanced proteomics technologies in this critical disease area. Roche is one of the world's leading research-oriented healthcare groups in the fields of pharmaceuticals, diagnostics and vitamins. Roche's innovative products and services address needs for prevention, diagnosis and treatment of disease, thus enhancing people's well-being and quality of life.